XORTX Therapeutics Business Summary

XORTX Therapeutics Inc. (XRTX) is a clinical-stage pharmaceutical company focused on developing and commercializing proprietary therapies for progressive kidney disease and gout. The company generates revenue through a biotech-standard model of strategic licensing, milestone payments, and future royalties, with a current emphasis on transitioning to commercial-stage operations. Its primary business segments are anchored by its late-stage clinical assets: XORLO™ (XRx-026), a proprietary oral oxypurinol formulation for allopurinol-intolerant gout targeted for a 2026 New Drug Application (NDA) filing, and XRx-008, an orphan-designated therapy for Autosomal Dominant Polycystic Kidney Disease (ADPKD). In October 2025, XORTX further diversified its pipeline by acquiring the VB4-P5 renal anti-fibrotic program. The company competes with established players like Otsuka Pharmaceutical, Centessa Pharmaceuticals, and Regeneron Pharmaceuticals, positioning itself as a specialized developer of xanthine oxidase inhibitors that address aberrant purine metabolism via the FDA’s 505(b)(2) accelerated regulatory pathway. The leadership team is led by Founder and CEO Dr. Allen Davidoff, a veteran drug developer who previously co-founded Stem Cell Therapeutics and served as a senior scientist at Cardiome Pharma. The executive suite was significantly strengthened in late 2024 with the appointment of CFO Dr. Michael Bumby, who brings 20 years of finance experience from Eli Lilly and Merus Labs, alongside Chief Medical Officer Dr. Stephen Haworth, a 25-year veteran of global drug development. Strategic growth is managed by Chief Business Officer Dr. Stacy Evans, a former Pfizer executive specializing in rare disease transactions. XORTX is governed by a high-pedigree board chaired by Anthony Giovinazzo, the former CEO of Cynapsus Therapeutics, and includes notable directors such as Abigail Jenkins, CEO of Gamida Cell, and Dr. Raymond Pratt, a leading nephrology expert. This team provides the deep regulatory and clinical expertise required to navigate the company’s transition from R&D to commercial-scale pharmaceutical distribution.